Okay, hear’s a revised and fact-checked version of teh provided text, incorporating facts from web searches to verify claims and update details where necessary. I’ve focused on ensuring accuracy regarding people’s current roles and the status of medications mentioned. I’ve also added a bit more context where helpful. Changes are noted at the end.
—
## Richard DiMarchi: A Legacy of Biotechnology and Mentorship
“The biggest reward is the people you produce,” he said. “I’ve contributed technology and drug candidates to the world, but I’ve also contributed the next generation of scientists capable of continuing to improve the world.”
Among his former students are leaders in the pharmaceutical industry and academia, including a former vice president of obesity research at Eli Lilly and Company, an associate dean, and a president of a life science group.
Many of DiMarchi’s former students continue to fuel biosciences work in Indiana. His first post-doctoral student, John Mayer, served as a key leader in lilly’s peptide research group for over a decade.During his tenure, the group substantially advanced several peptide clinical candidates, moast notably tirzepatide (Mounjaro®), now approved by the FDA for the treatment of type 2 diabetes and, more recently, for chronic weight management.
“I would not have had the career I had without his mentorship,” Mayer said.”Richard brings incredible passion and drive for the science, and his confidence rubs off and inspires those working with him.”
Archita Agrawal, one of DiMarchi’s last graduate students, is currently a postdoctoral scholar at the Salk Institute for Biological Studies, working with Alan Saghatelian on research